{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:58:46Z","timestamp":1761512326228},"reference-count":36,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autologous stem-cell transplantation is widely accepted as effective therapy for patients with relapsed aggressive B-cell non-Hodgkin lymphomas. Although 40\u201360% of younger patients with diffuse large cell lymphoma can expect to be cured, substantial numbers will experience a relapse. In addition, certain histologic subtypes are associated with particularly poor prognoses with combination chemotherapy alone (e.g., mantle cell lymphoma). Relatively few of these patients will experience long-term responses. Although other NHL subtypes are associated with more favorable prognoses in terms of overall survival, they are rarely cured (e.g., follicular lymphoma, chronic lymphocytic leukemia). Allogeneic transplantation has been increasingly utilized in patients with lymphoid malignancies but is associated with high toxicity. Recently, reduced-intensity conditioning regimens have shown encouraging results, attributed to graft-versus-lymphoma effects. This article discusses changes in the way autologous and allogeneic transplants may be carried out in the future to treat patients with lymphoid malignancies.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.390","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"390-397","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia"],"prefix":"10.1182","volume":"2006","author":[{"given":"Issa F.","family":"Khouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702281730500_R1","doi-asserted-by":"crossref","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al. ABMT as compared with salvage chemotherapy in relapses of chemosensitive NHL. N Engl J Med. 1995;333:1540\u20131545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"2019111702281730500_R2","doi-asserted-by":"crossref","unstructured":"Wierda W, O\u2019Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with recurrent\/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006;106:337\u2013345.","DOI":"10.1002\/cncr.21554"},{"key":"2019111702281730500_R3","unstructured":"Gribben JG, Nadler LM. Detection of minimal residual disease in patients with lymphomas using the polymerase chain reaction. Important Adv Oncol. 1994;;117\u2013129."},{"key":"2019111702281730500_R4","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Hosing C, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol. 2005;23:2240\u20132247.","DOI":"10.1200\/JCO.2005.08.012"},{"key":"2019111702281730500_R5","doi-asserted-by":"crossref","unstructured":"Khouri I, Saliba R, Hosing C, et al. Autologous stem cell vs non-myeloablative allogeneic transplantation after high-dose rituximab containing conditioning regimens for relapsed chemosensitive lymphoma. Blood. 2005;106:48a.","DOI":"10.1182\/blood.V106.11.48.48"},{"key":"2019111702281730500_R6","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28\u201333.","DOI":"10.1016\/j.exphem.2003.09.021"},{"key":"2019111702281730500_R7","doi-asserted-by":"crossref","unstructured":"Press OW, Eary JF, Gooley T, et al. A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2834\u20132942.","DOI":"10.1182\/blood.V96.9.2934"},{"key":"2019111702281730500_R8","doi-asserted-by":"crossref","unstructured":"Nademanee A, Forman S, Molina A, et al. A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106:2896\u20132902.","DOI":"10.1182\/blood-2005-03-1310"},{"key":"2019111702281730500_R9","doi-asserted-by":"crossref","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667\u2013678.","DOI":"10.1038\/sj.bmt.1703891"},{"key":"2019111702281730500_R10","doi-asserted-by":"crossref","unstructured":"Escalon MP, Champlin RE, Saliba RM, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin\u2019s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004; 22:2419\u20132423.","DOI":"10.1200\/JCO.2004.09.092"},{"key":"2019111702281730500_R11","doi-asserted-by":"crossref","unstructured":"Branson K, Chopra R, Kottaridis PD, et al. Role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol. 2002;20:4022\u20134031.","DOI":"10.1200\/JCO.2002.11.088"},{"key":"2019111702281730500_R12","doi-asserted-by":"crossref","unstructured":"Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428\u2013434.","DOI":"10.1182\/blood-2003-05-1406"},{"key":"2019111702281730500_R13","doi-asserted-by":"crossref","unstructured":"Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101:2015\u20132023.","DOI":"10.1182\/blood-2002-04-1261"},{"key":"2019111702281730500_R14","doi-asserted-by":"crossref","unstructured":"Van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521\u20133529.","DOI":"10.1182\/blood-2003-04-1205"},{"key":"2019111702281730500_R15","doi-asserted-by":"crossref","unstructured":"Maris MB, Sandmaier BM, Storer B, et al. Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma. Blood. 2005;106:329a.","DOI":"10.1182\/blood.V106.11.1130.1130"},{"key":"2019111702281730500_R16","doi-asserted-by":"crossref","unstructured":"Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004;104:3865\u20133871.","DOI":"10.1182\/blood-2004-03-1105"},{"key":"2019111702281730500_R17","doi-asserted-by":"crossref","unstructured":"Van Besien K, Carreras J, Zhang MJ, et al. Reduced intensity vs myeloablative conditioning for HLA-matched sibling transplantation in follicular lymphoma. Blood. 2005;106:656a.","DOI":"10.1182\/blood.V106.11.656.656"},{"key":"2019111702281730500_R18","doi-asserted-by":"crossref","unstructured":"Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 2005;23:1984\u20131992.","DOI":"10.1200\/JCO.2005.08.133"},{"key":"2019111702281730500_R19","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remission after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013\u20137023.","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"2019111702281730500_R20","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission. Cancer. 2003;98:2630\u20132635.","DOI":"10.1002\/cncr.11838"},{"key":"2019111702281730500_R21","doi-asserted-by":"crossref","unstructured":"Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood. 2005;105:2677\u20132684.","DOI":"10.1182\/blood-2004-10-3883"},{"key":"2019111702281730500_R22","doi-asserted-by":"crossref","unstructured":"Vose J, Loberiza F, Bierman, et al. Mantle cell lymphoma (MCL): induction therapy with hyperCVAD\/high-dose methotrexate and cytarabine (M-C) (+rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol. 2006;24:424s.","DOI":"10.1200\/jco.2006.24.18_suppl.7511"},{"key":"2019111702281730500_R23","doi-asserted-by":"crossref","unstructured":"Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749\u2013755.","DOI":"10.1182\/blood-2002-08-2476"},{"key":"2019111702281730500_R24","doi-asserted-by":"crossref","unstructured":"Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol. 2004;15:283\u2013290.","DOI":"10.1093\/annonc\/mdh069"},{"key":"2019111702281730500_R25","doi-asserted-by":"crossref","unstructured":"Khouri I, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407\u20134412.","DOI":"10.1200\/JCO.2003.05.501"},{"key":"2019111702281730500_R26","doi-asserted-by":"crossref","unstructured":"Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535\u20133542.","DOI":"10.1182\/blood-2004-06-2275"},{"key":"2019111702281730500_R27","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202\u20131210.","DOI":"10.1182\/blood-2003-07-2281"},{"key":"2019111702281730500_R28","doi-asserted-by":"crossref","unstructured":"Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885\u2013891.","DOI":"10.1182\/blood-2005-06-2395"},{"key":"2019111702281730500_R29","doi-asserted-by":"crossref","unstructured":"Jabbour E, Keating MJ, Champlin RE, Khouri IF. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant. 2004;34:289\u2013297.","DOI":"10.1038\/sj.bmt.1704593"},{"key":"2019111702281730500_R30","doi-asserted-by":"crossref","unstructured":"Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106:4389\u20134396.","DOI":"10.1182\/blood-2005-05-1778"},{"key":"2019111702281730500_R31","doi-asserted-by":"crossref","unstructured":"Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant Research. J Clin Oncol. 2005;23:5788\u20135794.","DOI":"10.1200\/JCO.2005.03.962"},{"key":"2019111702281730500_R32","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Sandmaier GM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3819\u20133829.","DOI":"10.1200\/JCO.2005.04.569"},{"key":"2019111702281730500_R33","doi-asserted-by":"crossref","unstructured":"Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3433\u20133438.","DOI":"10.1200\/JCO.2005.04.531"},{"key":"2019111702281730500_R34","doi-asserted-by":"crossref","unstructured":"Khouri, IF, Saliba RM, Keating MJ, et al. ZAP-70 status may not predict outcome after non-myeloablative allogeneic transplantation (NMT) in patients with chronic lymphocytic leukemia (CLL) who failed conventional chemotherapy. Blood. 2005;106:577a .","DOI":"10.1182\/blood.V106.11.2038.2038"},{"key":"2019111702281730500_R35","doi-asserted-by":"crossref","unstructured":"Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993\u20132003.","DOI":"10.1200\/JCO.2005.08.136"},{"key":"2019111702281730500_R36","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al. Non-myeloablative allogeneic transplantation (NMT) with T-cell replete graft for relapsed chemosensitive follicular lymphoma (FL): donor lymphocyte infusion (DLI) to convert stable mixed chimerism to full donor chimerism is not necessary in the absence of disease progression. Blood. 2005;106:1018a.","DOI":"10.1182\/blood.V106.11.3659.3659"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/390\/1091340\/390_397ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/390\/1091340\/390_397ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T01:24:59Z","timestamp":1628126699000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/390\/19695\/ReducedIntensity-Regimens-in-Allogeneic-StemCell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.390","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}